Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer’s Diflucan

Executive Summary

Oral antifungal fluconazole is "at least as effective and may be superior" to the standard treatment of I.V. amphotericin B in preventing recurrences of AIDS-related cryptococcal meningitis, HHS announced May 11. Conclusion was based on suspended U.S. multicenter trials of 205 patients conducted by Pfizer, the National Institute for Allergy and Infectious Disease AIDS Clinical Trials Group and its Mycoses Study Group. NIAID, based on preliminary results of the study, now recommends that Diflucan replace amphotericin B (Bristol-Myers Squibb's Fungizone) for the recurrence prevention treatment. Diflucan, in oral and I.V. forms, was approved Jan. 29 ("The Pink Sheet" Feb. 5, p. 5).

You may also be interested in...

China Lays Out Requirements For Biosimilar Extrapolation

In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.

Signs Of Hope But Obstacles Remain For Swiss Device MRA With EU

Without the MRA that allows unimpeded bilateral device trade between the EU and Switzerland, Swiss industry is having to find ways of limiting the damage that newly erected barriers will cause after the MDR comes into force.

Amneal Ready To Go Head-To-Head With Mylan’s Xulane In US

Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts